Stock Titan Trading tools for traders and investors.

-

02:21:22 AM

Last EVFM Stock Market News

EVFM - Evofem Biosciences Inc

02/23/21 8:00 AM

Nasdaq : EVFM

Evofem Biosciences to Present at H.C. Wainwright Global Life Sciences Conference

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it will present at the upcoming H.C. Wainwright Global Life Sciences Conference. Evofem's CEO, Saundra Pelletier, will provide an update on the commercialization of its non-hormonal,

RHEA-AI

neutral

02/18/21 8:00 AM

Nasdaq : EVFM

Evofem Biosciences to Report Fourth Quarter and Year-End 2020 Results and Provide Corporate Update on Thursday, March 4, 2021

Evofem Biosciences, Inc. (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company's financial results and business highlights for the fourth quarter and year ended December 31, 2020 as follows:DateThursday, March 4, 2021Time4:30

RHEA-AI

neutral

02/16/21 8:00 AM

Nasdaq : EVFM

Evofem Biosciences Launches U.S. Direct-to-Consumer Campaign to Accelerate Awareness of Phexxi(R), A Non-Hormonal Birth Control Option for Women

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced the launch of "Get Phexxi", a national direct-to-consumer (DTC) campaign aimed at broadening awareness of its non-hormonal, use-it-only-when-you-need-it birth control method, Phexxi (R) (lactic acid,

RHEA-AI

neutral

02/04/21 9:00 AM

Nasdaq : EVFM

Evofem Biosciences and NCODA Announce Collaboration to Educate Oncology Community about Phexxi(R), A Non-Hormonal Birth Control Option for Women with Cancer

Evofem Biosciences, Inc., (NASDAQ: EVFM) and NCODA (National Community Oncology Dispensing Association, Inc.), a premier educational platform for community and academic oncology practices nationwide, are launching a collaboration to positively impact the

RHEA-AI

very positive

01/12/21 9:05 AM

Nasdaq : EVFM

Evofem Biosciences Wins Business Intelligence Group's BIG Innovation Award 2021

Evofem Biosciences, Inc., (NASDAQ: EVFM) has been named a winner of Business Intelligence Group's 2021 BIG Innovation Award s for outstanding innovation with first-in-class non-hormonal prescription contraceptive vaginal gel, Phexxi(R) (lactic acid, citric

RHEA-AI

positive

12/22/20 7:00 AM

Nasdaq : EVFM

Evofem Biosciences to Participate in Medicaid National Drug Rebate Program for Phexxi(R) Effective January 1, 2021

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it has entered into an agreement with the U.S. Centers for Medicare and Medicaid Services (CMS) to participate in the Medicaid National Drug Rebate Program (NDRP), providing access to Phexxi(R) (lactic

RHEA-AI

neutral

12/21/20 9:00 AM

Nasdaq : EVFM

Evofem Biosciences to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it will present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference.Evofem's CEO, Saundra Pelletier, will provide updates on the commercialization of Phexxi(R) (lactic acid, citric acid and

RHEA-AI

neutral

12/17/20 7:00 AM

Nasdaq : EVFM

Evofem Biosciences Provides Update on Pivotal Phase 3 Trial of EVO100 for Prevention of Chlamydia and Gonorrhea

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that its pivotal Phase 3 trial, ' EVOGUARD ,' of EVO100 for the prevention of chlamydia and gonorrhea remains firmly on schedule. EVOGUARD was initiated and the first patient was enrolled in October

RHEA-AI

neutral

12/11/20 8:00 AM

Nasdaq : EVFM

Evofem Biosciences Announces Orange Book Listing of Two U.S. Patents for Phexxi(R)

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that two U.S. patents which cover Phexxi(R) (lactic acid, citric acid and potassium bitartrate) and its labeled indication are now listed in the U.S. Food and Drug Administration (FDA) publication

RHEA-AI

neutral

12/03/20 7:00 AM

Nasdaq : EVFM

The U.S. Department of Veterans Affairs Awards Contract to Evofem Biosciences for Phexxi(R)

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that the U.S. Department of Veterans Affairs (VA) has awarded the Company a contract for the purchase of Phexxi(R) (lactic acid, citric acid and potassium bitartrate) for a five-year period beginning

RHEA-AI

neutral